Anthera Pharmaceuticals (ANTH) Crashes on Failed Drug Trial; Cyclacel Pharmaceuticals (CYCC) Takes Upward Bounce


Anthera Pharmaceuticals Inc. (Nasdaq:ANTH) shares slumped more than 60% to touch a new 52-week low in after-hours trading Tuesday as the company said that the late-stage trial evaluating its non-porcine pancreatic enzyme replacement therapy (PERT) Sollpura versus an approved porcine PERT in cystic fibrosis patients with exocrine pancreatic insufficiency, narrowly failed to meet its primary target of non-inferiority margin with respect to fat absorption.

ANTH stock finished the regular session in positive territory by 2.03% (or +$0.04) at $2.01 with a total volume of 1.84M shares traded.

Anthera Pharmaceuticals, which focuses on developing and commercializing products to treat serious diseases, including exocrine pancreatic insufficiency due to cystic fibrosis and IgA nephropathy, has 41.96M shares outstanding. At close on Tuesday, the biopharmaceutical company had a market capitalization of $82.65M and ANTH stock one-year range was from $1.33 to $5.07 per share


Cyclacel Pharmaceuticals Inc. (Nasdaq:CYCC) stock soared 31.14% (or $1.23) to $5.18, and 2.48M of its shares changed hands on Tuesday’s trading session, representing a large increase in activity versus its average volume (3m) of 119,730 shares.

There appears to be no confirmed recent news from the biopharmaceutical company that may explain this movement in the stock.

Cyclacel Pharmaceuticals, which focuses on the development and commercialization of small molecule drugs for the treatment of cancer and other diseases, has 4.25M shares outstanding, market capitalization (intraday) of $21.75M and CYCC stock 52-week range is between $3.05 and $9.72 per share.


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at